Evidence for NADPH oxidase activation by GPR40 in pancreatic β-cells

References

• Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422(6928):173–176.
   PubMed Web of Science ®Google Scholar
• Graciano MF, Valle MM, Kowluru A, et al. Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets. Islets. 2011;3(5):213–223.
   PubMed Web of Science ®Google Scholar
• Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol. 2002;173(1):73–80.
   PubMed Web of Science ®Google Scholar
• Carpinelli AR, Picinato MC, Stevanato E, et al. Insulin secretion induced by palmitate–a process fully dependent on glucose concentration. Diabetes Metab. 2002;28(6 Pt 2):3S37–3S44. discussion 3S108-12.
   PubMed Web of Science ®Google Scholar
• Kotarsky K, Nilsson NE, Flodgren E, et al. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun. 2003;301(2):406–410.
   PubMed Web of Science ®Google Scholar
• Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303–11311.
   PubMed Web of Science ®Google Scholar
• Shapiro H, Shachar S, Sekler I, et al. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun. 2005;335(1):97–104.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Hinuma S. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res. 2005;33(2):171–173.
   PubMed Web of Science ®Google Scholar
• Poitout V. The ins and outs of fatty acids on the pancreatic beta cell. Trends Endocrinol Metab. 2003;14(5):201–203.
   PubMed Web of Science ®Google Scholar
• Schnell S, Schaefer M, Schöfl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol. 2007;263(1–2):173–180.
   PubMed Web of Science ®Google Scholar
• Del Guerra S, Bugliani M, D'Aleo V, et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis. 2010;20(1):22–25.
   PubMed Web of Science ®Google Scholar
• Vettor R, Granzotto M, De Stefani D, et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab. 2008;93(9):3541–3550.
   PubMed Web of Science ®Google Scholar
• Garrido DM, Corbett DF, Dwornik KA, et al. Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett. 2006;16(7):1840–1845.
   PubMed Web of Science ®Google Scholar
• Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem. 2008;51(22):7061–7064.
   PubMed Web of Science ®Google Scholar
• Bharate SB, Rodge A, Joshi RK, et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg Med Chem Lett. 2008;18(24):6357–6361.
   PubMed Web of Science ®Google Scholar
• Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett. 2010;1(6):290–294.
   PubMed Web of Science ®Google Scholar
• Houze JB, Zhu L, Sun Y, et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012;22(2):1267–1270.
   PubMed Web of Science ®Google Scholar
• Araki T, Hirayama M, Hiroi S, et al. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271–278.
   PubMed Web of Science ®Google Scholar
• Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012;52(7):1007–1016.
   PubMed Web of Science ®Google Scholar
• Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–1411.
   PubMed Web of Science ®Google Scholar
• Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92(1):29–39.
   PubMed Web of Science ®Google Scholar
• Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36(2):245–250.
   PubMed Web of Science ®Google Scholar
• Roma LP, Jonas JC. Nutrient metabolism, subcellular redox state, and oxidative stress in pancreatic islets and β-cells. J Mol Biol. 2020;432(5):1461–1493.
   PubMed Web of Science ®Google Scholar
• Babior BM. NADPH oxidase: an update. Blood. 1999;93(5):1464–1476.
   PubMed Web of Science ®Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245–313.
   PubMed Web of Science ®Google Scholar
• Nauseef WM. Assembly of the phagocyte NADPH oxidase. Histochem Cell Biol. 2004;122(4):277–291.
   PubMed Web of Science ®Google Scholar
• Oliveira HR, Verlengia R, Carvalho CR, et al. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes. 2003;52(6):1457–1463.
   PubMed Web of Science ®Google Scholar
• Rebelato E, Mares-Guia TR, Graciano MF, et al. Expression of NADPH oxidase in human pancreatic islets. Life Sci. 2012;91(7-8):244–249.
   PubMed Web of Science ®Google Scholar
• Morgan D, Rebelato E, Abdulkader F, et al. Association of NAD(P)H oxidase with glucose-induced insulin secretion by pancreatic beta-cells. Endocrinology. 2009;150(5):2197–2201.
   PubMed Web of Science ®Google Scholar
• Graciano MF, Santos LR, Curi R, et al. NAD(p)H oxidase participates in the palmitate-induced superoxide production and insulin secretion by rat pancreatic islets. J Cell Physiol. 2011;226(4):1110–1117.
   PubMed Web of Science ®Google Scholar
• Li N, Li B, Brun T, et al. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. Diabetes. 2012;61(11):2842–2850.
   PubMed Web of Science ®Google Scholar
• de Souza AH, Santos LR, Roma LP, et al. NADPH oxidase-2 does not contribute to β-cell glucotoxicity in cultured pancreatic islets from C57BL/6J mice. Mol Cell Endocrinol. 2017;439:354–362.
   PubMed Web of Science ®Google Scholar
• Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006;148(5):619–628.
   PubMed Web of Science ®Google Scholar
• Sum CS, Tikhonova IG, Neumann S, et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem. 2007;282(40):29248–29255.
   PubMed Web of Science ®Google Scholar
• Graciano MF, Leonelli M, Curi R, et al. Omega-3 fatty acids control productions of superoxide and nitrogen oxide and insulin content in INS-1E cells. J Physiol Biochem. 2016;72(4):699–710.
   PubMed Web of Science ®Google Scholar
• Meyer AJ, Dick TP. Fluorescent protein-based redox probes. Antioxid Redox Signal. 2010;13(5):621–650.
   PubMed Web of Science ®Google Scholar
• Morgan D, Oliveira-Emilio HR, Keane D, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia. 2007;50(2):359–369.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Kawaji A, Sato T, et al. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats. Pharmacol Res Perspect. 2017;5(4):e00340.
   Web of Science ®Google Scholar
• Sakuma K, Yabuki C, Maruyama M, et al. Fasiglifam (TAK-875) has dual potentiating mechanisms via Gαq-GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion. Pharmacol Res Perspect. 2016;4(3):e00237.
   PubMed Web of Science ®Google Scholar
• Graciano MF, Valle MM, Curi R, et al. Evidence for the involvement of GPR40 and NADPH oxidase in palmitic acid-induced superoxide production and insulin secretion. Islets. 2013;5(4):139–148.
   PubMed Web of Science ®Google Scholar
• Deglasse JP, Roma LP, Pastor-Flores D, et al. Glucose acutely reduces cytosolic and mitochondrial H2O2 in Rat pancreatic beta cells. Antioxid Redox Signal. 2019;30(3):297–313.
   PubMed Web of Science ®Google Scholar
• Takahashi HK, Santos LR, Roma LP, et al. Acute nutrient regulation of the mitochondrial glutathione redox state in pancreatic β-cells. Biochem J. 2014;460(3):411–423.
   PubMedGoogle Scholar
• Rebelato E, Abdulkader F, Curi R, et al. Control of the intracellular redox state by glucose participates in the insulin secretion mechanism. PLoS One. 2011;6(8):e24507.
   PubMed Web of Science ®Google Scholar
• Elsner M, Gehrmann W, Lenzen S. Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes. 2011;60(1):200–208.
   PubMed Web of Science ®Google Scholar
• Morgan D, Oliveira-Emilio HR, Keane D, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia. 2007;50(2):359–369.
   PubMed Web of Science ®Google Scholar
• Santos LR, Rebelato E, Graciano MF, et al. Oleic acid modulates metabolic substrate channeling during glucose-stimulated insulin secretion via NAD(P)H oxidase. Endocrinology. 2011;152(10):3614–3621.
   PubMed Web of Science ®Google Scholar
• Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J. 2002;4(11):1023–1024.
   PubMed Web of Science ®Google Scholar
• Fontayne A, Dang PM, Gougerot-Pocidalo MA, et al. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry. 2002;41(24):7743–7750.
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939–1945.
   PubMed Web of Science ®Google Scholar
• Kristinsson H, Bergsten P, Sargsyan E. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. Biochim Biophys Acta. 2015;1853(12):3248–3257.
   PubMed Web of Science ®Google Scholar
• Zinkevich NS, Gutterman DD. ROS-induced ROS release in vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol. 2011;301(3):H647–H653.
   PubMed Web of Science ®Google Scholar
• Reis J, Massari M, Marchese S, et al. A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. Redox Biol. 2020;32:101466.
   PubMed Web of Science ®Google Scholar
• Bánsághi S, Golenár T, Madesh M, et al. Isoform- and species-specific control of inositol 1,4,5-trisphosphate (IP3) receptors by reactive oxygen species. J Biol Chem. 2014;289(12):8170–8181.
   PubMed Web of Science ®Google Scholar
• Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1(4):245–258.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yan G, Li Y, et al. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother. 2010;64(9):647–651.
   PubMed Web of Science ®Google Scholar
• Wu J, Sun P, Zhang X, et al. Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 2012;113(4):1152–1158.
   PubMed Web of Science ®Google Scholar
• Abaraviciene S M, Lundquist I, Galvanovskis J, et al. Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms. PLoS One. 2008;3(5):e2182.
   PubMed Web of Science ®Google Scholar
• Kristinsson H, Smith DM, Bergsten P, et al. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology. 2013;154(11):4078–4088.
   PubMed Web of Science ®Google Scholar
• Natalicchio A, Labarbuta R, Tortosa F, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 2013;56(11):2456–2466.
   PubMed Web of Science ®Google Scholar
• Menon V, Lincoff AM, Nicholls SJ, et al. Fasiglifam-Induced Liver Injury in Patients With type 2 diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. Diabetes Care. 2018;41(12):2603–2609.
   PubMed Web of Science ®Google Scholar